Adherence with bisphosphonate therapy in US veterans with rheumatoid arthritis

J. Steuart Richards, Grant W. Cannon, Candace L. Hayden, Richard L. Amdur, Deana Lazaro, Ted R. Mikuls, Andreas M. Reimold, Liron Caplan, Dannette S. Johnson, Pascale Schwab, Bogdan N. Cherascu, Gail S. Kerr

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objective Pharmacy Benefits Management program data for patients enrolled in the Veterans Affairs Rheumatoid Arthritis (VARA) registry were linked with clinical data to determine bisphosphonate adherence and persistence among US veterans with rheumatoid arthritis (RA) and to determine factors associated with adherence. Methods The primary outcome measures were the duration of bisphosphonate therapy and the medication possession ratio (MPR). Patients with an MPR 32 months (OR 1.63, 95% CI 1.04-2.57). Whites were less likely to have a low MPR compared with nonwhites (OR 0.52, 95% CI 0.30-0.88). Conclusion Nonadherence with bisphosphonates was common in this cohort of RA patients and was associated with nonwhite ethnicity, a longer duration of RA disease, and a greater duration of bisphosphonate therapy.

Original languageEnglish (US)
Pages (from-to)1864-1870
Number of pages7
JournalArthritis Care and Research
Volume64
Issue number12
DOIs
StatePublished - Dec 2012

Fingerprint

Diphosphonates
Veterans
Rheumatoid Arthritis
Therapeutics
Registries
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Rheumatology

Cite this

Richards, J. S., Cannon, G. W., Hayden, C. L., Amdur, R. L., Lazaro, D., Mikuls, T. R., ... Kerr, G. S. (2012). Adherence with bisphosphonate therapy in US veterans with rheumatoid arthritis. Arthritis Care and Research, 64(12), 1864-1870. https://doi.org/10.1002/acr.21777

Adherence with bisphosphonate therapy in US veterans with rheumatoid arthritis. / Richards, J. Steuart; Cannon, Grant W.; Hayden, Candace L.; Amdur, Richard L.; Lazaro, Deana; Mikuls, Ted R.; Reimold, Andreas M.; Caplan, Liron; Johnson, Dannette S.; Schwab, Pascale; Cherascu, Bogdan N.; Kerr, Gail S.

In: Arthritis Care and Research, Vol. 64, No. 12, 12.2012, p. 1864-1870.

Research output: Contribution to journalArticle

Richards, JS, Cannon, GW, Hayden, CL, Amdur, RL, Lazaro, D, Mikuls, TR, Reimold, AM, Caplan, L, Johnson, DS, Schwab, P, Cherascu, BN & Kerr, GS 2012, 'Adherence with bisphosphonate therapy in US veterans with rheumatoid arthritis', Arthritis Care and Research, vol. 64, no. 12, pp. 1864-1870. https://doi.org/10.1002/acr.21777
Richards JS, Cannon GW, Hayden CL, Amdur RL, Lazaro D, Mikuls TR et al. Adherence with bisphosphonate therapy in US veterans with rheumatoid arthritis. Arthritis Care and Research. 2012 Dec;64(12):1864-1870. https://doi.org/10.1002/acr.21777
Richards, J. Steuart ; Cannon, Grant W. ; Hayden, Candace L. ; Amdur, Richard L. ; Lazaro, Deana ; Mikuls, Ted R. ; Reimold, Andreas M. ; Caplan, Liron ; Johnson, Dannette S. ; Schwab, Pascale ; Cherascu, Bogdan N. ; Kerr, Gail S. / Adherence with bisphosphonate therapy in US veterans with rheumatoid arthritis. In: Arthritis Care and Research. 2012 ; Vol. 64, No. 12. pp. 1864-1870.
@article{c1f17449cd4a481a90949e56f220a9e5,
title = "Adherence with bisphosphonate therapy in US veterans with rheumatoid arthritis",
abstract = "Objective Pharmacy Benefits Management program data for patients enrolled in the Veterans Affairs Rheumatoid Arthritis (VARA) registry were linked with clinical data to determine bisphosphonate adherence and persistence among US veterans with rheumatoid arthritis (RA) and to determine factors associated with adherence. Methods The primary outcome measures were the duration of bisphosphonate therapy and the medication possession ratio (MPR). Patients with an MPR 32 months (OR 1.63, 95{\%} CI 1.04-2.57). Whites were less likely to have a low MPR compared with nonwhites (OR 0.52, 95{\%} CI 0.30-0.88). Conclusion Nonadherence with bisphosphonates was common in this cohort of RA patients and was associated with nonwhite ethnicity, a longer duration of RA disease, and a greater duration of bisphosphonate therapy.",
author = "Richards, {J. Steuart} and Cannon, {Grant W.} and Hayden, {Candace L.} and Amdur, {Richard L.} and Deana Lazaro and Mikuls, {Ted R.} and Reimold, {Andreas M.} and Liron Caplan and Johnson, {Dannette S.} and Pascale Schwab and Cherascu, {Bogdan N.} and Kerr, {Gail S.}",
year = "2012",
month = "12",
doi = "10.1002/acr.21777",
language = "English (US)",
volume = "64",
pages = "1864--1870",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "12",

}

TY - JOUR

T1 - Adherence with bisphosphonate therapy in US veterans with rheumatoid arthritis

AU - Richards, J. Steuart

AU - Cannon, Grant W.

AU - Hayden, Candace L.

AU - Amdur, Richard L.

AU - Lazaro, Deana

AU - Mikuls, Ted R.

AU - Reimold, Andreas M.

AU - Caplan, Liron

AU - Johnson, Dannette S.

AU - Schwab, Pascale

AU - Cherascu, Bogdan N.

AU - Kerr, Gail S.

PY - 2012/12

Y1 - 2012/12

N2 - Objective Pharmacy Benefits Management program data for patients enrolled in the Veterans Affairs Rheumatoid Arthritis (VARA) registry were linked with clinical data to determine bisphosphonate adherence and persistence among US veterans with rheumatoid arthritis (RA) and to determine factors associated with adherence. Methods The primary outcome measures were the duration of bisphosphonate therapy and the medication possession ratio (MPR). Patients with an MPR 32 months (OR 1.63, 95% CI 1.04-2.57). Whites were less likely to have a low MPR compared with nonwhites (OR 0.52, 95% CI 0.30-0.88). Conclusion Nonadherence with bisphosphonates was common in this cohort of RA patients and was associated with nonwhite ethnicity, a longer duration of RA disease, and a greater duration of bisphosphonate therapy.

AB - Objective Pharmacy Benefits Management program data for patients enrolled in the Veterans Affairs Rheumatoid Arthritis (VARA) registry were linked with clinical data to determine bisphosphonate adherence and persistence among US veterans with rheumatoid arthritis (RA) and to determine factors associated with adherence. Methods The primary outcome measures were the duration of bisphosphonate therapy and the medication possession ratio (MPR). Patients with an MPR 32 months (OR 1.63, 95% CI 1.04-2.57). Whites were less likely to have a low MPR compared with nonwhites (OR 0.52, 95% CI 0.30-0.88). Conclusion Nonadherence with bisphosphonates was common in this cohort of RA patients and was associated with nonwhite ethnicity, a longer duration of RA disease, and a greater duration of bisphosphonate therapy.

UR - http://www.scopus.com/inward/record.url?scp=84870510208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870510208&partnerID=8YFLogxK

U2 - 10.1002/acr.21777

DO - 10.1002/acr.21777

M3 - Article

VL - 64

SP - 1864

EP - 1870

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 12

ER -